BCH and Rocky Mountain Cancer Centers announce prostate cancer technology partnership

The only medical campus north of Denver to offer Truebeam® and Brainlab ExacTrac Dynamic® — reduces an entire course of radiation therapy from 45 visits to just five

Boulder Community Health (BCH) and Rocky Mountain Cancer Centers-Boulder (RMCC-Boulder) announced a partnership that brings an exponential leap forward for diagnosing and treating prostate cancer with leading-edge technologies housed within the Tebo Family Medical Pavilion on the Foothills Medical Campus.

Treatments through the new partnership include sophisticated, integrated technologies for planning and delivering high-precision image-guided radiotherapy using the Varian TrueBeam® radiotherapy system — which reduces a full course of radiation therapy from 45 visits to just five in select patients — along with Brainlab® ExacTrac Dynamic to ensure precise positioning and treatment delivery accuracy during radiotherapy. BCH’s Foothills Medical Campus is the first north of Denver to offer prostate cancer patients these two technologies for a shorter course of radiotherapy.

“Adding these advanced radiation oncology services opens the door to shorter treatment options for men in our community with prostate cancer,” says RMCC-Boulder radiation oncologist Dario Pasalic, M.D., who has worked extensively with patients diagnosed with prostate cancer and published on the topic in impactful journals such as Cancer. “As a leading provider of cancer care services, we have worked with the physicians from BMC and BCH for many years. We are grateful for this partnership, and for what it will bring to our patients diagnosed with prostate cancer.”

“As a radiation oncologist in the Boulder community for six years now, I am extremely excited and honored to have these cutting-edge technologies available to best serve our patients,” adds radiation oncologist Patrick Richard, M.D., also from RMCC-Boulder. “Our patients with prostate cancer are very

thoughtful about their care and want to have all options discussed with them. Our new capabilities can best support their goals, and they now have state-of-the-art radiation options available close to home in Boulder County.”

The partnership also includes General Electric’s Discovery DR system for positron emission tomography (PET) molecular imaging using prostate-specific membrane antigen (PSMA). PSMA-PET provides high-quality images and more specificity for detecting prostate cancer than traditional imaging used in the past, giving physicians the ability to find and treat prostate cancer more effectively. PSMA is used for initial staging of certain intermediate-to-high risk cases, as well as restaging recurrent prostate cancer.

Patients receiving radiotherapy treatment or diagnostic imaging through the partnership experience seamless care between BMC urologists Drs. Carolyn Fronczak and Stephen Siegel, RMCC radiation oncology treatment teams and BCH’s diagnostic imaging specialists.

“During our 100-year history of caring for our community, BCH has always placed an emphasis on providing our patients with local access to the latest and most advanced treatments available across a wide range of services. This partnership aligns well with our strategic vision of partnering to create and care for the healthiest community in the nation. BCH’s Foothills Medical Campus is the first in Boulder County to offer the combination of these highly innovative technologies. We are extremely proud to be able to provide them for our patients with prostate cancer,” said Darryl Brown, BCH’s Associate Vice President of Strategy and Business Development.